Increased Intra Ocular Pressure, Optic Nerve Damage, And Vision Loss Are Noticed In Patients Diagnosed With Glaucoma.

You’ll have to get yourself tested at an ophthalmologist, who’ll recommend you glass or contact lenses to correct your vision. Increased intra ocular pressure, optic nerve damage, and vision loss are noticed in patients diagnosed with glaucoma. As soon as you notice one or more symptoms, you must visit an ophthalmologist for treatment. In rare cases, chemical injuries to the eyes, eye infections, etc. are also sometimes responsible for glaucoma. At the slightest hint of any of these symptoms, consult a vet as early as possible. Long-term abuse of this drug can lead to addiction. The doctor also checks the size and colon of the cornea. This develops pressure and damages the optical nerves. If you experience a blurred vision after lasik surgery, then it need not be always an indication of the laser eye surgery gone wrong. Conjunctivitis can be treated with the help of medications and eye drops. Our eyes are very delicate organs and must therefore be treated with utmost care. Examining The Facts For Straightforward Eye Bags Methods | Leah Mitchell TalkCucumbers have cooling properties and are also capable of reducing blood vessel size, thereby reducing puffiness.

In company news, Lakeland Industries ( LAKE ) rallied Thursday after the maker of protective equipment for medical personel reported higher-than-expected Q2 net income and revenue. no dataNet income from continuing operations fell to $0.20 per share during the three months ended July 31 from a $0.50 per share gain during the same quarter last year but still doubled up the $0.10 per share consensus estimate by analysts. Revenue rose 9% over year-ago levels to $22.3 million, also exceeding the Capital IQ consensus by around $300,000. LAKE shares were up almost 13% at $10.58 apiece, earlier climbing to a session high of $10.97 a share. In other sector news, (+) AERI, (+45.8%) Roclatan drug candidate meets primary efficacy endpoint during Phase III testing, with the potential glaucoma therapy demonstrating statistical superiority over the market-leading latanoprost eye medication. (-) GBSN, (-29.1%) Nasdaq stock market warns the company’s stock could be delisted unless it can increase its share price above the stock exchange’s $1 minimum. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Copyright (C) 2016 All rights reserved. Unauthorized reproduction is strictly prohibited.

For the original version including any supplementary images or video, visit

Leave a Reply

Your email address will not be published. Required fields are marked *